Search results for: Downs
What Drives Innovators? Pioneer Mark Humayun, MD, PhD, Shares His Story & Vision for Ophthalmology
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 093″] Over two decades ago, Mark Humayun – who will co-chair our upcoming OIS@ASRS – helped launch a “moonshot” that would eventually restore vision for retinitis pigmentosa patients. In this podcast we discuss what drives him and what’s next for ophthalmology. Podcast Guest Mark Humayun, MD, PhD Mark S. Humayun, MD,…
Read MoreKOL Corner: Can Complement Inhibitors Treat Macular Degeneration?
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 080″] The complement system is a promising target for drugs being developed to treat macular degeneration. But success has been elusive. A leading KOL and two CEOs explain what the future of the field may be. Podcast Transcript Tom Salemi: Hi, everyone, welcome back to the OIS Podcast. This is your…
Read MoreCan Apellis Find a way to Inhibit the Complement System & Treat Intermediate AMD?
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 078″] Clinical trials of complement inhibitors recently have produced some disappointing results, but Apellis remains committed to demonstrating its own inhibitor can help bring relief to people battling geographic atrophy and AMD. 10 Top Topics in this OIS Podcast: What’s this about a Face Transplant? A successful spinout from Potentia. How…
Read MoreApellis IPO Road Show Takes Different Route
Putting Brakes on IPO, Apellis Lines Up Private Funding As the stock market took its 2016 nosedive, geographic atrophy drug developer Apellis Pharmaceuticals joined the parade of biotech companies that put the brakes on planned public offerings and turned back to private equity for the capital to drive their development programs. Apellis filed last fall…
Read MoreInotek’s Southwell & McVicar Have Designs on Treating Glaucoma
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 070″] Inotek CEO David Southwell and William K. McVicar PhD Executive Vice President, Chief Scientific Officer, share Inotek’s plan to bring to market a new first-line for glaucoma sufferers. Podcast Guest David P. Southwell Mr. Southwell has been President and CEO since August 2014, and led Inotek through its IPO and…
Read MoreCan Spark Phase III Results Ignite Gene Therapy?
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 060″] Jeffrey D. Marrazzo, Co-Founder and CEO of Spark Therapeutics, discusses the successful Phase III trial of its lead candidate, SPK-RPE65, was able to improve functional vision in patients with a rare form of a genetic disorder known as RPE65-mediated inherited retinal dystrophies. SPK-RPE65 is intended to treat rare blinding conditions…
Read MoreCEO Tom Burns Has Even Bigger Plans For Glaukos
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 052″] MIGs leader Glaukos Corp. raised over $100 million in an IPO to expand its already commanding reach in the white hot MIGs Market. Now the company commands a market capitalization close to $1 billion, enriching the venture investors who committed more than $100 million in venture capital to the company.…
Read MoreHere is How Big Companies Innovate
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 044″] Leaders of Alcon, AMO, Valeant and Zeiss Discuss the Role of Innovation in their Success. Podcast Transcript Tom Salemi: Hi, welcome back to the OIS Podcast. This is Tom Salemi, your host. Thank you so much for joining us today. If you tuned in last week, you heard from J.…
Read MoreMasters of the Universe
Moderator: Jim Mazzo Jim Mazzo is the Executive Chairman and CEO for AcuFocus. AcuFocus specializes in presbyopia correction and is known for its revolutionary KAMRA inlay which was recently FDA approved. View Full Profile Panelists: Jeff George Jeff was appointed to lead Alcon in May 2014. As the global leader in eye care, Alcon provides…
Read MoreCEOs Share Their ‘Second Acts’ On Way to Building Successful Companies
Building a successful biotech or biopharma company typically turns on a sentinel event — the pivot, as William J. Link, PhD, Managing Director of Versant Ventures calls it. That can involve a complete shift in a company’s focus. Link hosted a panel at the Ophthalmology Innovation Summit in Chicago, where CEOs and founders explained how…
Read MoreNeovista – A Challenging Journey
Versant Ventures Managing Director William J. Link PhD talks about the journey of NeoVista through all of its ups and downs. Ultimately Neovista was able to get its CE Mark, but failed to get approved by the FDA due to a spiral of “stacking” risks. Presenter: William J. Link, PhD Bill was Founder, Chairman and…
Read More